Calidi Biotherapeutics Q2 FY26 net loss narrows 26.32% to $4.2 million; general and administrative expense drops 48% to $1.6 million

Reuters2026/08/13 20:37

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Calidi Biotherapeutics posted a net loss attributable to common stockholders of USD 4.2 million, or USD 2.94 a share, in Q2 2026.
Loss narrowed from USD 5.7 million a year earlier, while research and development expense held at USD 2.6 million.
General and administrative expense fell 48% to USD 1.6 million, reflecting a USD 1.5 million reduction versus Q2 2025.
Cash was USD 4.1 million at June 30, down from USD 5.6 million at Dec. 31, with USD 0.2 million restricted cash.
FDA pre-IND feedback backed the CLD-401 strategy, with first patient dosing targeted for Q1 2027, CEO Eric Poma said.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131630PRIMZONEFULLFEED9809779) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Calidi Biotherapeutics Q2 FY26 net loss narrows 26.32% to $4.2 million; general and administrative expense drops 48% to $1.6 million

You may also like

Crypto prices